Trial Profile

Study to Evaluate the Effects of Two Doses Over 48 Hours of MEDI6012 on Apolipoprotein B100 Metabolism in Subjects With Stable Atherosclerotic Cardiovascular Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEDI 6012 (Primary)
Indications Atherosclerosis; Cardiovascular disorders; Carotid artery diseases; Coronary artery disease; Peripheral arterial disorders
Focus Therapeutic Use

Most Recent Events

10 Dec 2020 Status changed from recruiting to discontinued.
28 Mar 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
28 Mar 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com